Ascentage Pharma Group International (6855.HK)

HKD 48.6

(-1.02%)

Long Term Debt Summary of Ascentage Pharma Group International

  • Ascentage Pharma Group International's latest annual long term debt in 2023 was 1.17 Billion CNY , down -6.8% from previous year.
  • Ascentage Pharma Group International's latest quarterly long term debt in 2024 Q2 was 959.14 Million CNY , down 0.0% from previous quarter.
  • Ascentage Pharma Group International reported annual long term debt of 1.26 Billion CNY in 2022, up 23.24% from previous year.
  • Ascentage Pharma Group International reported annual long term debt of 1.02 Billion CNY in 2021, up 117.01% from previous year.
  • Ascentage Pharma Group International reported quarterly long term debt of 1.17 Billion CNY for 2023 Q4, down 0.0% from previous quarter.
  • Ascentage Pharma Group International reported quarterly long term debt of 1.17 Billion CNY for 2023 FY, down -6.8% from previous quarter.

Annual Long Term Debt Chart of Ascentage Pharma Group International (2023 - 2016)

Historical Annual Long Term Debt of Ascentage Pharma Group International (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 1.17 Billion CNY -6.8%
2022 1.26 Billion CNY 23.24%
2021 1.02 Billion CNY 117.01%
2020 473.05 Million CNY 5035.76%
2019 9.21 Million CNY 106.66%
2018 4.45 Million CNY 54.81%
2017 2.87 Million CNY 509.96%
2016 472 Thousand CNY 0.0%

Peer Long Term Debt Comparison of Ascentage Pharma Group International

Name Long Term Debt Long Term Debt Difference
Uni-Bio Science Group Limited 30.61 Million HKD -3752.055%
CK Life Sciences Int'l., (Holdings) Inc. 4.27 Billion HKD 72.403%